CClinicalTrials.gg
CompletedNCT03918395SPARTAUpdated Mar 31, 2020

Supplemental Protein And Resistance Training Adaptations

An interventional study of Placebo beverage and Protein-polyphenol beverage in Hypertrophy, sponsored by University of Exeter. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-31.

Sponsored by University of Exeter · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Sep 2018, registered Apr 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Chronic resistance training has been shown to increase muscle cross-sectional area, volume and strength. Individuals participating in a resistance training program may wish to consume protein supplements to aid recovery and maximise adaptation. Furthermore, antioxidants have been shown to aid recovery from acute bouts of exercise. However, the effect of antioxidants combined with protein on long term-training adaptation is not fully understood.

This study will combine measures of muscle size, muscle strength and function, and the underlying changes in muscle metabolism in order to assess the effect of consuming a combined protein-antioxidant supplement during a 30 session resistance training program.

Read the detailed description

Supplemental protein ingestion is an established method for augmenting gains in fat free mass, muscle strength and muscle cross sectional area following a period of resistance exercise training. In addition to protein, supplements high in polyphenols such as berry and pomegranate extract are believed to be an effective method of reducing soreness and facilitating recovery following a single bout of resistance exercise.

However, whilst polyphenols are shown to facilitate recovery from a single session of resistance exercise, their effect on adaptations to repeated bouts of resistance exercise are unknown. Asking this question will allow a detailed investigation of the mechanisms by which protein-polyphenol ingestion may affect adaptations to resistance exercise training when compared to a non protein or polyphenol containing placebo, which is an important yet underexplored area

02

Conditions studied

  • Hypertrophy

Browse trials for

03

In context

Hypertrophy

656 studies on the registry are indexed under Hypertrophy; 87 are open to participants now.

This study's enrollment of 32 is below the median of 50 across 460 interventional studies indexed under Hypertrophy.

Browse Hypertrophy studies →

Lead sponsor

University of Exeter is the lead sponsor of 138 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male and Female
  • 18 - 40 years of age
  • Recreationally active

Exclusion criteria

Exclusion Criteria:

  • Any diagnosed metabolic impairment (e.g. type 1 or 2 Diabetes). Such impairments can affect skeletal muscle metabolism
  • Any diagnosed cardiovascular disease or hypertension
  • Use of nutritional supplements (e.g. protein, polyphenols, vitamins, antioxidants) as use of nutritional supplements during the study period may interfere with the physiological responses to the supplements of interest administered in this study.
  • Habitual dietary protein intake \<0.8 g/kg/day or >1.6 g/kg/day as calculated with a three day diet diary. Habitually low protein may impair adaptations to resistance exercise training and a habitually excessive protein intake may negate the benefit of protein supplementation.
  • Current musculoskeletal injury that may impair exercise performance or may be exacerbated due to this studies exercise protocol.
  • Resistance trained (participating in structured resistance exercise 3 or more times per week for >6 months), endurance trained (participating in structured endurance exercise for >6h per week for >6 months), or sedentary participants as these are not the populations of interest.
  • Chronic use of anti-inflammatory medicines prior to the study and unwillingness to refrain from taking anti-inflammatory medications during the study as these medications may affect skeletal muscle metabolism and/or adaptation to exercise.
  • Individuals who carry an epi-pen, or those with a diagnosed allergy or who believe that they have an allergy to milk or milk products, crustacean shellfish, tree nuts, or peanuts
  • Individuals with a severe allergy to egg, fish, wheat or soy ingredients as the product is manufactured in a facility that contains these ingredients
  • Individuals with non removable metallic implants (including heart pacemaker, cochlea implants, medication pumps, surgical clips, plates or screws) or claustrophobia
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo beverage

    Dietary Supplement: Placebo beverage

  • Active comparator
    Protein-Polyphenol supplement

    Protein-polyphenol beverage

    Dietary Supplement: Protein-polyphenol beverage

Interventions

  • Dietary supplementPlacebo beverage

    A placebo beverage will be consumed both post-exercise and pre-bed

  • Dietary supplementProtein-polyphenol beverage

    A protein-polyphenol beverage will be consumed both post-exercise and pre-bed

06

What researchers measure

Primary outcomes

  1. Change in cross-sectional area of quadriceps muscle group

    The cross-sectional area of the muscles comprising the thigh after 30 training sessions will be compared to pre-training values. This will be measured using MRI.

    Time frame: After 30 training sessions (approx. 10 weeks)

Secondary outcomes

  1. Change in quadriceps muscle group volume

    The volume of the muscles comprising the thigh after 30 training sessions will be compared to pre-training values. This will be measured using MRI.

    Time frame: After 30 training sessions (approx. 10 weeks)

  2. Change in knee extensor isokinetic total work

    Bilateral knee extensor isokinetic total work will be assessed before and after the training program by quantifying work completed over 30 isokinetic quadriceps contractions on an isokinetic dynamometer.

    Time frame: After 30 training sessions (approx. 10 weeks)

  3. Change in maximal isometric peak torque

    Knee extensor isometric peak torque will be assessed before and after the training program using an isokinetic dynamometer.

    Time frame: After 30 training sessions (approx. 10 weeks)

  4. Change in maximal isokinetic peak torque

    Knee extensor isokinetic peak torque over 3 repetitions will be assessed before and after the training program using an isokinetic dynamometer.

    Time frame: After 30 training sessions (approx. 10 weeks)

  5. Change in muscle protein synthesis assessed using the stable isotope Deuterium Oxide

    The enrichment of deuterated alanine (from the deuterium oxide heavy water stable isotope tracer) in vastus lateralis biopsy samples will be measured relative to the non-deuterated alanine. The change over 48 hours will be measured pre- and post-training to calculate a fractional synthesis rate (% day).

    Time frame: After 30 training sessions (approx. 10 weeks)

  6. Perceived quadriceps muscle soreness:

    Soreness will be assessed at the start of each training session using a validated visual analogue scale (VAS)

    Time frame: After 30 training sessions (approx. 10 weeks)

07

Study locations

1 site
  • University of Exeter
    Exeter, Devon EX1 2LU, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03918395
Lead sponsor
University of Exeter
Responsible party
Sponsor
First posted
Apr 17, 2019
Start date
Sep 1, 2018
Primary completion
Dec 21, 2019
Completion
Dec 21, 2019
Last update
Mar 31, 2020

Study contacts

Francis Stephens, PhD
principal investigator · University of Exeter

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion